The 1 analysts offering 12-month price forecasts for Plus Therapeutics Inc have a median target of 7.50, with a high estimate of 7.50 and a low estimate of 7.50. The median estimate represents a +223.28% increase from the last price of 2.32.
The current consensus among 1 polled investment analysts is to Buy stock in Plus Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$5.72
Reporting Date Mar 09
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.